

## Corrections and clarifications in *BNF for Children*

Date posted	Edition	Versions affected	Clarification or correction		Comment
			Location	Detail	
28 July 2010	2010–2011	Book	Page 733 Section 14.1, Impaired Immune Response	<p>Footnotes 1 and 2 referred to in this section are missing at the bottom of p.733. The two footnotes should be:</p> <ol style="list-style-type: none"> <li>1. Live vaccines should be postponed until at least 3 months after stopping high-dose systemic corticosteroids and at least 6 months after stopping other immunosuppressive drugs or generalised radiotherapy (at least 12 months after discontinuing immunosuppressants following bone-marrow transplantation)</li> <li>2. Use of normal immunoglobulin should be considered after exposure to measles (see p.764) and varicella–zoster immunoglobulin considered after exposure to chickenpox or herpes zoster (see p. 768).</li> </ol>	The error will be corrected for the print edition of BNFC 2011–2012

2 March 2010	2009	Digital	Section 3.1, Management of acute asthma	<p>The maximum dose of magnesium sulphate to be given in severe or life-threatening acute asthma is unclear. The maximum dose should read:</p> <p>Children over 2 years with severe acute asthma may be helped by intravenous infusion of <b>magnesium sulphate</b> 40mg/kg (max. 2g) over 20 minutes</p>	Online versions of BNFC 2009 have been corrected. An update to correct this error will be made available for other digital versions of BNFC 2009
15 February 2010	2009	Book and digital	Page 771, column 1 Section 15.1.3	<p>The maximum dose of glycopyrronium bromide for the control of upper airways secretion and hypersalivation applies to each individual dose not the total daily dose. The dose should read as follows:</p> <ul style="list-style-type: none"> <li>• <b>By mouth</b> Child 1 month–18 years 40–100 micrograms/kg (max. 2 mg) 3–4 times daily, adjusted according to response</li> </ul>	<p>The error will be corrected for the print edition of BNFC 2010</p> <p>Online versions of BNFC 2009 have been corrected. An update to correct this error will be made available for other digital versions of BNFC 2009</p>

14 October 2009	2009	Book and digital	Page 778, column 2 Section 15.1.4.3	<p>The route of administration of fentanyl for analgesia and respiratory depression with assisted ventilation in intensive care is unclear.</p> <p>The dose should read as follows:</p> <ul style="list-style-type: none"> <li>• <b>By intravenous administration</b>  <b>Neonate</b> initially by <i>intravenous injection</i> 1-5 micrograms/kg, followed by an <i>intravenous infusion</i>, dose dependent on indication and response  <b>Child 1 month – 18 years</b> initially by <i>intravenous injection</i> 1-5 micrograms/kg, followed by an <i>intravenous infusion</i>, dose dependent on indication and response</li> </ul>	<p>The error will be corrected for the print edition of BNFC 2010</p> <p>Digital versions of BNFC 2009 have been corrected</p>
17 August 2009	2009	Book and digital	Page 242, column 2 Section 4.6	<p>The preparation information for generic domperidone suspension is incorrect: the strength of this product is 5mg/5mL, <b>not</b> 5mg/mL. The entry should read as follows:</p> <p><b>Suspension</b>, domperidone 5mg/5mL, net price 200-mL pack = £7.00</p>	<p>The error will be corrected for the print edition of BNFC 2010</p> <p>Digital versions of BNFC 2009 have been corrected</p>

8 July 2009	2009	Book	Page 259, column 1 Section 4.7.2	<p>The route of administration for tramadol for the treatment of postoperative pain in children is incorrect. The dose should be administered by intravenous injection and <b>not</b> by mouth.</p> <p>The dose should read as follows:</p>	The error will be corrected for the print edition of BNFC 2010
	2008	Book & digital	Page 258, column 1 Section 4.7.2	<ul style="list-style-type: none"> <li>By intravenous injection (over 2–3 minutes) <b>Child 12–18 years</b> 100 mg initially then 50 mg every 10–20 minutes if necessary up to total max. 250 mg (including initial dose) in first hour, <i>then</i> 50–100 mg every 4–6 hours, max. 600 mg daily</li> </ul>	Digital versions of BNFC 2009 have been corrected
17 October 2007	2007	Book & Digital	Page 74, column 1 Section 1.5	<p>The dose of intravenous ciclosporin for the treatment of refractory ulcerative colitis in children is incorrect. The dose by intravenous infusion should read:</p>	<p>The error will be corrected for the print edition of BNFC 2008</p> <p>Online versions of BNFC 2007 have been corrected. An update to correct this error will be available for other digital versions of BNFC 2007</p>
				<ul style="list-style-type: none"> <li><b>Child 3–18 years</b> initially 0.5–1 mg/kg twice daily; dose adjusted according to blood-ciclosporin concentration and response</li> </ul>	

8 January 2007	2006	Book	Page 750 Top of column 1 and column 2	Column header should read 'Antimalarials' not 'Antihistamines'	The error will be corrected for BNFC 2007
27 November 2006	2006	Book & digital	Page 854, column 1	BNFC2006 shows an incorrect email address for IVAX Pharmaceuticals.	Queries to IVAX should instead be made by post, telephone, or fax
13 November 2006	2006	Book & digital	page 268 right-hand column  section 4.8.1	The strength of Nitrazepam oral suspension is incorrect. The preparation should read as follows:	The error will be corrected for BNFC 2007
				Oral suspension, nitrazepam 2.5 mg/5 mL, net price 150 mL = £5.30. Label: 1, 8	
3 November 2006	2006	Book & digital	page 261 right-hand column  section 4.8.1	In the paragraph on Administration (under Phenobarbital), the rate of injection is incorrect and the statement on intravenous injection should read:	The error will be corrected for BNFC 2007. Note that the rate of injection shown on p.272 (section 4.8.2) is correct.
				For <i>intravenous injection</i> , dilute to a concentration of 20 mg/mL with Water for Injections; give over 20 minutes (no faster than 1 mg/kg/minute).	

31 October 2006	2006	Book & digital	page 680  section 14.4	<p>The strength of one of the Tuberculin Purified Protein Derivative preparations is incorrect. The preparation entry should read:</p> <p><b>Injection</b>, heat-treated products of growth and lysis of appropriate <i>Mycobacterium</i> spp. 20 units/mL (2 units/0.1-mL dose) (for routine use), 1.5-mL vial; 100 units/mL (10 units/0.1-mL dose), 1.5-mL vial</p>	The error will be corrected for BNFC 2007
22 May 2006	2005	Book & digital	page 164, column 1 & section 3.1.1	<p>The dose shown under the entry for <i>Oxis<sup>®</sup> Turbohaler<sup>®</sup></i> should read as follows:</p> <p><b>Chronic asthma</b></p> <ul style="list-style-type: none"> <li>By inhalation of powder</li> </ul> <p><b>Child 6–18 years</b> 9 micrograms 1–2 times daily; occasionally up to 36 micrograms daily may be needed (max. single dose 9 micrograms); reassess treatment if additional doses required on more than 2 days a week</p> <p><b>Relief of bronchospasm</b></p> <ul style="list-style-type: none"> <li>By inhalation of powder</li> </ul> <p><b>Child 6–18 years</b> 4.5–9 micrograms</p> <p><b>Prevention of exercise-induced bronchospasm</b></p> <ul style="list-style-type: none"> <li>By inhalation of powder</li> </ul> <p><b>Child 6–18 years</b> 4.5–9 micrograms before exercise</p>	BNFC 2006 will show the correct doses

1 October 2005	2005	Book (first print only— see Comment)	page 290, column 1	<p>There is an error in the dose of cefalexin for a child aged 12–18 years. The dose should read as follows:</p> <p><b>Child 12–18 years</b> 500 mg 2–3 times daily, increased to 1–1.5 g 3–4 times daily for severe infection</p>	Digital versions of <i>BNF for Children</i> have been amended to show the correct dose. So too have copies of the book reprinted in October 2005
----------------	------	--	--------------------	--	--